Physician's Weekly1d
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Medscape21h
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Medscape8d
GLP-1 RAs Unlikely to Increase Suicide Risk
Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...
MarketWatch8d
Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug
Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...
pharmaphorum6d
Large study points to benefits - and risks - of GLP-1 drugs
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...
pharmaphorum7d
Small study finds GLP-1 drug can curb excess alcohol use
Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...
University of Dayton9d
5-Time Champ: Student Run Flyer Fund Ranks #1 Again
The University of Dayton's Flyer Investments Fund has once again secured the #1 spot in the nation, according to the annual survey conducted by the Center for Investment Research. This prestigious ...